文献速递炎症性肠病

系统综述与Meta分析:乌司奴单抗或维得利珠单抗治疗抗肿瘤坏死因子难治性克罗恩病患者的有效性

Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor.
PubMed 文献 · Aliment Pharmacol Ther · 2021-12-01

该系统综述与Meta分析比较了乌司奴单抗与维得利珠单抗在抗肿瘤坏死因子(TNF)难治性克罗恩病(CD)患者中的有效性,纳入5项研究共1026例患者(乌司奴单抗659例,维得利珠单抗367例)。第14周时两组临床缓解、无激素临床缓解和生物学缓解率相似;第52周时乌司奴单抗在临床缓解、无激素临床缓解、生物学缓解和治疗持续率方面均优于维得利珠单抗。

要点

  • 抗TNF难治性CD患者中,第14周乌司奴单抗与维得利珠单抗的临床缓解、无激素临床缓解和生物学缓解率相似。
  • 第52周乌司奴单抗的临床缓解(OR 1.87)、无激素临床缓解(OR 1.56)、生物学缓解(OR 1.86)和治疗持续(OR 2.37)均优于维得利珠单抗。
  • 纳入研究均为高质量,其中4项为回顾性、1项为前瞻性。

核心结论

  • 在抗TNF难治性CD患者中,乌司奴单抗与维得利珠单抗在诱导治疗方面有效性相似,但在维持治疗方面乌司奴单抗似乎比维得利珠单抗更有效。

研究设计与样本

  • 通过PubMed、EMBASE和Cochrane Library检索截至2021年3月27日的文献,纳入比较乌司奴单抗与维得利珠单抗在抗TNF难治性CD患者中有效性的研究,共5项研究(4项回顾性、1项前瞻性),合计1026例患者,其中乌司奴单抗组659例、维得利珠单抗组367例。

主要发现

  • 第14周时,乌司奴单抗组与维得利珠单抗组的临床缓解率(OR 1.36;95%CI:0.74-2.47;I²=50%)、无激素临床缓解率(OR 1.24;95%CI:0.79-1.92;I²=52%)和生物学缓解率(OR 0.80;95%CI:0.50-1.28;I²=0%)相似。
  • 第52周时,乌司奴单抗组相比维得利珠单抗组的临床缓解率更高(OR 1.87;95%CI:1.18-2.98;I²=0%)。
  • 第52周时,乌司奴单抗组相比维得利珠单抗组的无激素临床缓解率更高(OR 1.56;95%CI:1.23-1.97;I²=0%)。
  • 第52周时,乌司奴单抗组相比维得利珠单抗组的生物学缓解率更高(OR 1.86;95%CI:1.03-3.37;I²=29%)。
  • 第52周时,乌司奴单抗组相比维得利珠单抗组的治疗持续率更高(OR 2.37;95%CI:1.56-3.62;I²=0%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ustekinumab and vedolizumab are commonly used after anti-tumour necrosis factor (TNF) failure in patients with Crohn's disease (CD). No randomised controlled trial has compared these drugs. AIMS: To compare the effectiveness of ustekinumab and vedolizumab in CD patients refractory to anti-TNF. METHODS: From PubMed, EMBASE and the Cochrane Library, through March 27, 2021, we identified studies that compared ustekinumab and vedolizumab in patients with CD refractory to anti-TNF. The main outcomes were clinical remission and steroid-free clinical remission at weeks 14 and 52. Secondary outcomes were biological remission and treatment persistence. We computed pooled odds ratios (OR) and 95% confidence intervals (CI) using random effects meta-analysis. RESULTS: We identified 1513 reports. Among them, 38 studies were assessed for eligibility and five studies were included. All studies included were of high quality: four were retrospective and one was prospective. Among 1026 patients, 659 received ustekinumab and 367 received vedolizumab. At week 14, clinical remission (OR 1.36; 95%CI: 0.74-2.47; I2 = 50%), steroid-free clinical remission (OR 1.24; 95%CI: 0.79-1.92; I2 = 52%) and biological remission (OR 0.80; 95%CI: 0.50-1.28; I2 = 0%) rates were similar between the two treatments. At week 52, ustekinumab was associated with higher rates of clinical remission (OR 1.87; 95% CI: 1.18-2.98; I2 = 0%), steroid-free clinical remission (OR 1.56; 95% CI: 1.23-1.97; I2 = 0%), biological remission (OR 1.86; 95% CI: 1.03-3.37; I2 = 29%) and treatment persistence (OR 2.37; 95% CI: 1.56-3.62; I2 = 0%). CONCLUSION: In patients with CD refractory to anti-TNF, ustekinumab and vedolizumab are similarly effective in induction, but as maintenance treatment, ustekinumab appears to be more effective than vedolizumab.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Parrot L, Dong C, Carbonnel F, et al. Systematic review with meta-analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2021. PMID: 34854100. doi:10.1111/apt.16714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。